Literature DB >> 22710198

Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers.

Stéphane Vignot1, Benjamin Besse, Fabrice André, Jean-Philippe Spano, Jean-Charles Soria.   

Abstract

The identification of predictive factors of response is critical for the development and appropriate use of anti-cancer agents. The evaluation of biomarkers is usually performed by analyzing the primary tumor tissues but this approach does not take into account potential discrepancies between primary tumor and secondary lesions. This review proposes to describe currently available data regarding differential expression of established biomarkers between primary tumor and matched metastasis. In light of recent data, the need of iterative biopsies in metastatic setting has been suggested but technical and methodological limits in such analyses should not be ignored and this strategy cannot be definitively validated. Complementary studies are still needed since the question of spatial and temporal variability of biomarkers in solid tumors is clearly a key issue in an era where personalized therapy is strongly advocated by clinicians, researchers and patients.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22710198     DOI: 10.1016/j.critrevonc.2012.05.002

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  30 in total

Review 1.  Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.

Authors:  P Ramos; M Bentires-Alj
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

Review 2.  Translating metastasis-related biomarkers to the clinic--progress and pitfalls.

Authors:  François-Clément Bidard; Jean-Yves Pierga; Jean-Charles Soria; Jean Paul Thiery
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

3.  Assessment of chromosomal rearrangements helps to differentiate multiple lung primary cancers from metastases.

Authors:  Laura Bonanno; Alberto Pavan; Stefano Indraccolo
Journal:  Transl Lung Cancer Res       Date:  2019-12

4.  Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors.

Authors:  Rashmi S Goswami; Keyur P Patel; Rajesh R Singh; Funda Meric-Bernstam; E Scott Kopetz; Vivek Subbiah; Ricardo H Alvarez; Michael A Davies; Kausar J Jabbar; Sinchita Roy-Chowdhuri; Alexander J Lazar; L Jeffrey Medeiros; Russell R Broaddus; Rajyalakshmi Luthra; Mark J Routbort
Journal:  Clin Cancer Res       Date:  2015-02-18       Impact factor: 12.531

5.  Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet.

Authors:  Cornelia Kolberg-Liedtke; Rachel Wuerstlein; Oleg Gluz; Florian Heitz; Muriel Freudenberger; Elena Bensmann; Andreas du Bois; Ulrike Nitz; Enrico Pelz; Matthias Warm; Monika Ortmann; Elena Sultova; Sara Y Brucker; Ronald E Kates; Tanja Fehm; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2020-12-15       Impact factor: 2.860

6.  Molecular image-directed biopsies: improving clinical biopsy selection in patients with multiple tumors.

Authors:  Stephanie A Harmon; Michael J Tuite; Robert Jeraj
Journal:  Phys Med Biol       Date:  2016-10-03       Impact factor: 3.609

7.  Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer.

Authors:  Willemijne A M E Schrijver; Petra van der Groep; Laurien Dc Hoefnagel; Natalie D Ter Hoeve; Ton Peeters; Cathy B Moelans; Paul J van Diest
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

8.  Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.

Authors:  C Le Tourneau; X Paoletti; N Servant; I Bièche; D Gentien; T Rio Frio; A Vincent-Salomon; V Servois; J Romejon; O Mariani; V Bernard; P Huppe; G Pierron; F Mulot; C Callens; J Wong; C Mauborgne; E Rouleau; C Reyes; E Henry; Q Leroy; P Gestraud; P La Rosa; L Escalup; E Mitry; O Trédan; J-P Delord; M Campone; A Goncalves; N Isambert; C Gavoille; M Kamal
Journal:  Br J Cancer       Date:  2014-04-24       Impact factor: 7.640

9.  The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.

Authors:  Laura Pizzuti; Maddalena Barba; Marco Mazzotta; Eriseld Krasniqi; Marcello Maugeri-Saccà; Teresa Gamucci; Rossana Berardi; Lorenzo Livi; Corrado Ficorella; Clara Natoli; Enrico Cortesi; Daniele Generali; Nicla La Verde; Alessandra Cassano; Emilio Bria; Luca Moscetti; Andrea Michelotti; Vincenzo Adamo; Claudio Zamagni; Giuseppe Tonini; Domenico Sergi; Daniele Marinelli; Giancarlo Paoletti; Silverio Tomao; Andrea Botticelli; Paolo Marchetti; Nicola Tinari; Antonino Grassadonia; Maria Rosaria Valerio; Rosanna Mirabelli; Maria Agnese Fabbri; Nicola D'Ostilio; Enzo Veltri; Domenico Corsi; Ornella Garrone; Ida Paris; Giuseppina Sarobba; Icro Meattini; Mirco Pistelli; Francesco Giotta; Vito Lorusso; Carlo Garufi; Antonio Russo; Marina Cazzaniga; Pietro Del Medico; Mario Roselli; Angela Vaccaro; Letizia Perracchio; Anna di Benedetto; Theodora Daralioti; Isabella Sperduti; Ruggero De Maria; Angelo Di Leo; Giuseppe Sanguineti; Gennaro Ciliberto; Patrizia Vici
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

Review 10.  Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives.

Authors:  Carmen Criscitiello; Fabrice André; Alastair M Thompson; Michele De Laurentiis; Angela Esposito; Lucia Gelao; Luca Fumagalli; Marzia Locatelli; Ida Minchella; Franco Orsi; Aron Goldhirsch; Giuseppe Curigliano
Journal:  Breast Cancer Res       Date:  2014       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.